Published in final edited form as:

Bioorg Med Chem Lett. 2016 October 15; 26(20): 5078–5081. doi:10.1016/j.bmcl.2016.08.081.

Studies Towards the Improvement of an Anti-Cocaine Monoclonal Antibody for Treatment of Acute Overdose

Bin Zhou^{a,b}, Lisa M Eubanks^{a,b}, Nicholas T Jacob^a, Beverly Ellis^{a,b}, Amanda J Roberts^c, and Kim D Janda^{a,b,d,*}

^a Department of Chemistry, The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.

^b Department of Immunology and Microbial Sciences, The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.

^c Committee on Neurobiology of Addictive Disorders, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.

^d Worm Institute of Medical Research (WIRM), The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.

Abstract

There is currently no clinically-approved antidote for cocaine overdose. Efforts to develop a therapy via passive immunization have resulted in a human monoclonal antibody, GNCgzk, with a high affinity for cocaine ($K_d = 0.18$ nM). Efforts to improve the production of antibody manifolds based on this antibody are disclosed. The engineering of an HRV 3C protease cleavage site into the GNCgzk IgG has allowed for increased production of a $F(ab')_2$ with a 20% superior capacity to reduce mortality for cocaine overdose in mice.

Graphical abstract

It is estimated that there are about 1.5 million people 12 and older that are current users of cocaine in the United States¹, and from 2001 to 2014 there has been a 42% increase in the

* Corresponding author. Tel: +1 858 784 2516. Fax: +1 858 784 2595. kdjanda@scripps.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

number of deaths attributed to cocaine use.² Additionally, studies indicate cocaine remains the most commonly used illicit stimulant in Europe, with an estimated 2.4 million users aged 15 to 34.³ Despite its prevalence, there is no currently available clinical antidote to treat acute cocaine toxicity. Methods to treat cocaine overdose only lie in management of the symptoms: arrhythmia, seizure, and hyperthermia.⁴ Thus, it is desirable to find a more direct antidote therapy for cocaine intoxication. One approach is to target the cocaine molecules themselves using a monoclonal antibody to sequester the cocaine in the blood stream and lower the relative concentration of drug affecting the central nervous system, and mitigating the psychoactive effects.

Previously, we developed a murine monoclonal antibody (mAb), GNC92H2 IgG, which exhibited therapeutic utility in rodent models with an affinity of approximately 2 nM for cocaine.⁵⁻⁷ This success was followed by the isolation of a hybridoma from a transgenic xenomouse producing a fully human mAb, GNCgzk.⁸⁻¹⁰ Compared to GNC92H2, this clone was found to produce antibodies with a greatly increased affinity for cocaine ($K_d = 0.18$ nM) as well as higher specificity against cocaine metabolites.¹⁰ Importantly, GNCgzk has a fast association rate ($k_{on} = 4.3 \times 10^7 \text{ M}^{-1}\text{S}^{-1}$), and this key property allowed for GNCgzk to demonstrate complete prophylactic protection from cocaine overdose. Moreover, the administration of the GNCgzk IgG was able to decrease lethality by 40% when administered 3 minutes after administration of an LD₅₀ dose of cocaine. This was improved though the construction of the F(ab')₂ fragment of the GNCgzk antibody, which demonstrated complete protection from lethality at 3 mins post-cocaine treatment.¹⁰ However, production of the F(ab')₂ suffered from a low yield following pepsin digestion of the GNCgzk IgG, limiting its clinical viability.

Many advances in antibody technology have allowed for the *ex vivo* improvement of mAb manifolds.¹¹ In order to lower the production costs of producing the GNCgzk IgG, a new single-chain variable fragment with an IgG1 crystallizable fragment (scFv-Fc) construct was designed (Figure 1). The benefits of using the scFv construct lies in the ease of production: engineering flexibility, speed of biosynthesis, and higher yields.¹² However, the lack of a constant region also results in rapid blood clearance, which is overcome by combining the scFv with a Fc.¹³ Combined, this scFv-Fc construct provides a format with more easily tunable pharmacokinetic (PK) properties.

PK studies initiated by examining the serum stability of the GNCgzk scFv-Fc. Mice were injected with 15 mg/kg of purified fusion protein, and blood samples were taken at 1, 24, 48, and 72 hours after injection. The concentration of scFv-Fc retained in the blood was measured by surface plasmon resonance (SPR) using a Biacore 3000 instrument (GE Healthcare) equipped with a research-grade CM5 sensor chip. A cocaine-BSA conjugate was immobilized on the chip and samples from each time point were passed through the flow cell.¹⁴ The GNCgzk scFv-Fc exhibited an adequate serum half-life of 3.9 days (Figure 2) in mice, an improvement over the GNC92H2 counterpart.⁷

The GNCgzk scFv-Fc was tested in a cocaine overdose model in mice.¹⁵ Male CD-1 mice (Charles River Laboratories, Wilmington, MA) were used in overdose studies and catheters implanted as previously described.¹⁰ Briefly, animals were administered a dose of

cocaine hydrochloride (NIDA, Rockville, MD) dissolved in sterile 0.9% saline, intraperitoneally (i.p.) at 10 mL/kg. The GNCgzk scFv-Fc was found to decrease mortality by 30% at 66 mg/kg 3 minutes after administration of 110 mg/kg cocaine (Figure 3a). Seizures and ataxia are also phenotypic effects of cocaine overdose. However, these data were skewed due to the high mortality rate of the control group, preventing a good measure of seizures and ataxia (Figure 3b & c).

The effects of the GNCgzk scFv-Fc were not as robust as the IgG or F(ab')₂ format in reducing mortality. The GNCgzk F(ab')₂ had previously shown complete survival of all animals at a dose of 66 mg/kg.¹⁰ In order to more readily access the F(ab')₂ construct, a human rhinovirus (HRV) 3C protease cleavage site (LEVLFQGP) was engineered into the hinge region of the GNCgzk IgG plasmid, encoding the modified IgG^{HRV} protein. The use of the HRV 3C protease resulted in quantitative conversion of the IgG^{HRV} to F(ab')₂^{HRV}.

A radioimmunoassay (RIA) was employed¹⁶ in order to determine the affinity of the GNCgzk IgG^{HRV}, F(ab')₂^{HRV}, and scFv-Fc for cocaine. Pooled serum samples from each treatment group were incubated with L-[benzoyl1–3,4–³H(M)]-cocaine tracer (spec. activity = 26 Ci/mmol; PerkinElmer, Boston, MA), and through equilibrium dialysis using 5000 Da MWCO plates (Harvard Apparatus, Holliston, MA) with a cold competitor, the affinity of each construct was obtained.¹⁷ The relative affinity (K_d) for cocaine for each construct was determined to be 3.8, 33.3, and 8.8 μM for the IgG^{HRV}, F(ab')₂^{HRV}, and scFv-Fc, respectively. The relatively high K_d for the F(ab')₂^{HRV} was surprising, since it had been previously demonstrated to be the most effective intervention.¹⁰

To explore the possibility that the HRV cleavage site affected the capacity of the F(ab')₂^{HRV} construct in preventing acute cocaine toxicity, it was tested in mice by I.P. injection 3 minutes after a cocaine dose of 110 mg/kg was administered. Although it did not exhibit the complete loss of mortality as previously demonstrated, it outperformed the GNCgzk IgG^{HRV} by reducing the mortality by 50%, as opposed to 30% (Figure 4a). It also exhibited a strong attenuation of ataxia and modest reduction in the seizure severity score over the 40 min time course (Figure 4c & d). Thus, despite having the highest K_d, the F(ab')₂^{HRV} still outperformed its IgG^{HRV} counterpart.

There is currently no antidote for the treatment of acute cocaine overdose in the clinic. Efforts to produce such an antidote through passive immunization have produced a viable mAb, GNCgzk. While the engineering of a scFv-Fc construct of the GNCgzk mAb imparted easier production, it lacks the same efficacy as the full IgG and F(ab')₂ counterparts. Thus, in order to make the F(ab')₂ more accessible, an HRV cleavage site was engineered in to the hinge region of the IgG plasmid to give quantitative yields of F(ab')₂ from the IgG construct. This F(ab')₂ was able to decrease mortality by 20% over the IgG, as well as attenuate phenotypic behaviors of cocaine overdose. Investigations into the use of the GNCgzk F(ab')₂ are ongoing and will consist of further characterization of the binding mode between the IgG and F(ab')₂, as well as further development as a clinically-viable cocaine antidote.

Acknowledgments

Funding for this study was provided by the National Institute on Drug Abuse (DA008590 to K.D.J.) and National Institute of Health (TLR1TR001113 to N.T.J.). This is manuscript #29403 from TSRI.

Abbreviations

mAb	monoclonal antibody
scFv	single-chain variable-fragment
Fc	crystallizable fragment
PK	pharmacokinetic
SPR	surface plasmon resonance
HRV	human rhinovirus

References

- Center for Behavioral Health Statistics and Quality. Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health (HHS Publication No. SMA 15-4927, NSDUH Series H-50). 2015. Retrieved from <http://www.samhsa.gov/data/>
- National Institute on Drug Abuse. [July 28, 2016] Cocaine. Retrieved from <https://www.drugabuse.gov/drugs-abuse/cocaine>
- European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2016: Trends and Developments. Publications Office of the European Union; Luxembourg: 2016.
- Longo, DL.; Fauci, AS.; Kasper, DL.; Hauser, SL.; Jameson, J.; Loscalzo, J., editors. Harrison's Principles of Internal Medicine. 18e. McGraw-Hill; New York, NY: 2012.
- Carrera MR, Ashley JA, Zhou B, Wirsching P, Koob GF, Janda KD. Proc. Natl. Acad. Sci. U.S.A. 2000; 97:6202–6206. [PubMed: 10823960]
- Carrera MRA, Trigo JM, Wirsching P, Roberts AJ, Janda KD. Pharmacol. Biochem. Behav. 2005; 81:709–714. [PubMed: 16005948]
- Treweek JB, Roberts AJ, Janda KD. Pharmacol. Biochem. Behav. 2011; 98:474–484. [PubMed: 21356233]
- Mendez MJ, Green LL, Corvalan JRF, Jia X-C, Maynard-Currie CE, Yang X-D, Gallo ML, Louie DM, Lee DV, Erickson KL, Luna J, Roy CMN, Abderrahim H, Kirschenbaum F, Noguchi M, Smith DH, Fukushima A, Hales JF, Finer MH, Davis CG, Zsebo KM, Jakobovits A. Nat Genet. 1997; 15:146–156. [PubMed: 9020839]
- Green LL. J. Immunol. Methods. 1999; 231:11–23. [PubMed: 10648924]
- Treweek JB, Janda KD. Mol. Pharmaceutics. 2012; 9:969–978.
- Lerner RA. Nature Reviews Immunology. 2016; 16:498–508.
- Yang, J.; Rader, C. Antibody Methods and Protocols. Vol. 901. Humana Press; Totowa, NJ: 2012. Methods in Molecular Biology; p. 209-232.
- Olafsen T, Kenanova VE, Wu AM. Nature protocols. 2006; 1:2048–2060. [PubMed: 17487194]
- Bremer PT, Kimishima A, Schlosburg JE, Zhou B, Collins KC, Janda KD. Angewandte Chemie. 2016; 128:3836–3839.
- Animals were housed four per cage prior to study with a 12:12 h light-dark cycle. Water and food pellets were available *ad libitum*. All experiments were carried out in accordance with the *Guide for the Care and Use of Laboratory Animals* and were approved by the Animal Care and Use Committee at The Scripps Research Institute.
- Müller, R. Immunochemical Techniques Part E: Monoclonal Antibodies and General Immunoassay Methods. Vol. 92. Elsevier; 1983. Methods in Enzymology; p. 589-601.

17. Cai X, Whitfield T, Hixon MS, Grant Y, Koob GF, Janda KD. J. Med. Chem. 2013; 56:3701–3709. [PubMed: 23627877]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 1.
Cartoon depiction of the different antibody manifolds of GNCgzk with a summary of key characteristics.

Figure 2. Average time-dependent serum concentrations of GNCgzk scFv-Fc determined by SPR (mean $\pm$ SEM; n = 9). Half-life on the GNCgzk scFV-Fc was determined to be 3.9 days.

Figure 3.

Overdose study for the GNCgzk scFv-Fc. a. Survival graph of treatment administered 3-mins post i.p. infusion of 110 mg/kg of cocaine (n = 10). b. LOCF of ataxia score for each treatment group 40 mins following cocaine infusion (mean + SEM). c. LOCF of severity of cocaine-induced seizures 40 mins following cocaine infusion (mean + SEM).

Figure 4.

180 mg/kg IgG, 132 mg/kg F(ab')₂, cocaine injected i.p. at 110 mg/kg, treatment administered 3 mins after injection over 1 min by CC (n = 10). a. Survival graph for treatment group 40 minutes post-cocaine infusion. b. LOCF of ataxia score over time for each treatment group (mean + SEM). c. LOCF of seizure severity of each treatment group 40 mins post-cocaine infusion (mean + SEM). **P* < 0.05 determined by Fisher's Exact Test (two-tailed).